Identification and assessment of the 1,6-dihydroxy-pyridin-2-one moiety as privileged scaffold for HBV ribonuclease H inhibition
- 5 February 2024
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 223, 105833
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01 AI150610, R21 AI124672)
- Gilead Sciences
This publication has 27 references indexed in Scilit:
- Predicted structure of the hepatitis B virus polymerase reveals an ancient conserved protein foldProtein Science, 2022
- Physical methods for enhancing drug absorption from the gastrointestinal tractAdvanced Drug Delivery Reviews, 2021
- Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease HAntiviral Research, 2017
- Inhibition of hepatitis B virus replication by N -hydroxyisoquinolinediones and related polyoxygenated heterocyclesAntiviral Research, 2017
- Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitorsAntiviral Research, 2016
- Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitorsAntiviral Research, 2016
- Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activityAntiviral Research, 2014
- β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activityAntiviral Research, 2013
- Kinetics of Hepatitis B Surface Antigen Decline During 3 Years of Telbivudine Treatment in Hepatitis B e Antigen–Positive PatientsHepatology, 2010
- Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide AnaloguesHepatology, 2010